TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1707230

Group type: COMPARATOR
Intervention: Low-dose Adriamycin (doxorubicin, 20 mg/m2) alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with bleomycin and vincristine (ABV)
Number of subjects: 61
Study: 6762308

Group type: EXPERIMENTAL
Intervention: Riopan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maaloxan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 3900236

Group type: EXPERIMENTAL
Intervention: 100,000 U aqueous penicillin G
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 53
Study: 30101333

Group type: EXPERIMENTAL
Intervention: DGA diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAD diet
Number of subjects: 52
Study: 27654344

Group type: EXPERIMENTAL
Intervention: Point-of-care hemostatic testing
Number of subjects: 7402

Group type: COMPARATOR
Intervention: Control phase (standard care)
Number of subjects: 7402
Study: 24347034

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 39
Study: 22078076

Group type: EXPERIMENTAL
Intervention: Dementia care mapping
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Person centred care
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual dementia care
Number of subjects: 194
Study: 21246944

Group type: EXPERIMENTAL
Intervention: Pyrantel tartrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole 2.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duramectin 1%
Number of subjects: 0
Study: 18250181

Group type: EXPERIMENTAL
Intervention: Nebulised furosemide 40 mg
Number of subjects: 20
Study: 16777503

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11472698

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO(4); 40 mmol/24 hours)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9595981

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8000815

Group type: EXPERIMENTAL
Intervention: 15% glucose solution (1 g kg‐1 body mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-energy sweetened placebo
Number of subjects: 16
Study: 3291901

Group type: EXPERIMENTAL
Intervention: Split-course treatment (227 patients)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Continuous-course treatment (212 patients)
Number of subjects: 439
Study: 29601271

Group type: EXPERIMENTAL
Intervention: Gain-framed message from an expert source with high number of 'likes'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social endorsement and source type
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 0
Study: 27027660

Group type: EXPERIMENTAL
Intervention: Single-session psychoeducation treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: Delayed treatment comparison control group
Number of subjects: 67
Study: 24670774

Group type: EXPERIMENTAL
Intervention: Immediate removal (0h)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Intermediate removal (6h)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Delayed removal (24h)
Number of subjects: 221
Study: 21939626

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (HHS) 2 ml/kg (7.2% NaCl with 6% hydroxyethyl starch) over 10 min
Number of subjects: 203

Group type: COMPARATOR
Intervention: HES infusion over 10 min
Number of subjects: 203
Study: 20109196

Group type: EXPERIMENTAL
Intervention: Mobile phone-based care model for outpatient cardiac rehabilitation using ICT, including mobile phones with accelerometer sensors, WellnessDiary software, video and teleconferencing for mentoring, and educational multimedia content.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional community-based rehabilitation program.
Number of subjects: 0
Study: 18617492

Group type: EXPERIMENTAL
Intervention: Talking Parents, Healthy Teens (intervention)
Number of subjects: 569
Study: 15946573

Group type: EXPERIMENTAL
Intervention: (188)Re-HEDP
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: (188)Re-HEDP plus pamidronate
Number of subjects: 48
Study: 12017373

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg b.i.d.
Number of subjects: 20
Study: 10215733

Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg b.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 250 mg b.d.)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: OAC
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: OMC
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Second-line therapy (quadruple regimen: omeprazole 20 mg b.d., tripotassium dicitrato bismuthate 120 mg q.d.s., tetracycline 500 mg q.d.s., metronidazole 400 mg t.d.s.)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Second-line therapy (2-week proton pump inhibitor-based triple therapy)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Repeat 1-week regimen
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Second-line therapy (1-week proton pump inhibitor-based triple therapy)
Number of subjects: 308
Study: 7832264

Group type: EXPERIMENTAL
Intervention: Mentholated cigarettes
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-mentholated cigarettes
Number of subjects: 29
Study: 2242408

Group type: EXPERIMENTAL
Intervention: Progabide as an adjuvant therapy for partial seizures
Number of subjects: 0
Study: 331503

Group type: EXPERIMENTAL
Intervention: Diclophenac sodium (Voltaren)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone (Tanderil)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 31989505

Group type: EXPERIMENTAL
Intervention: Conventional training (CT) plus RAGT
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: RAGT
Number of subjects: 51
Study: 30925953

Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Number of subjects: 90

Group type: COMPARATOR
Intervention: Citicoline
Number of subjects: 90
Study: 30294868

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide + chlorhexidine/alcohol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Chlorhexidine/alcohol
Number of subjects: 22
Study: 27085296

Group type: EXPERIMENTAL
Intervention: Locking intramedullary nails
Number of subjects: 72

Group type: COMPARATOR
Intervention: Locking plates
Number of subjects: 72
Study: 25496052

Group type: EXPERIMENTAL
Intervention: Interactive balance training program (4 weeks, twice a week) with wearable sensors providing visual/auditory feedback
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Interactive balance training program
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: User experience of the training program
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 22266603

Group type: EXPERIMENTAL
Intervention: 48-week pegylated interferon (PEG-IFN) alfa-2a 180 mcg/week and ribavirin (RBV) 15mg/kg/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 24-week pegylated interferon (PEG-IFN) alfa-2a 180 mcg/week and ribavirin (RBV) 15mg/kg/day
Number of subjects: 105
Study: 19721059

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combined individual and group cognitive-behavioral therapy (CBT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study: 17709294

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BoNT-A) treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (10 subjects)
Number of subjects: 29
Study: 16298160

Group type: EXPERIMENTAL
Intervention: Depot system (goserelin acetate, 'Zoladex')
Number of subjects: 82

Group type: COMPARATOR
Intervention: Vial system (leuprorelin acetate, 'Prostap')
Number of subjects: 82
Study: 12215937

Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline 0.9% as placebo
Number of subjects: 150
Study: 10361663

Group type: EXPERIMENTAL
Intervention: 0.2 mg intrathecal morphine sulfate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3 mg intrathecal morphine sulfate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.4 mg intrathecal morphine sulfate
Number of subjects: 60
Study: 7572762

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus penicillin V (group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Amikacin plus carbenicillin or ceftazidime (group B)
Number of subjects: 108
Study: 2111784

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 6265222

Group type: EXPERIMENTAL
Intervention: Standardized coarse wheat bran preparation, 0.5 kg‐1 body weight per day for 4 or 8 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Standardized coarse wheat bran preparation, 0.5 kg‐1 body weight per day for 4 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Standardized coarse wheat bran preparation, 0.5 kg‐1 body weight per day for 8 weeks
Number of subjects: 7
Study: 30302577

Group type: EXPERIMENTAL
Intervention: Sufficient exemplar training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Existing narrowly focused low-intensity intervention
Number of subjects: 78
Study: 27714506

Group type: EXPERIMENTAL
Intervention: Consecutive balneological treatment for 2 weeks (10 sessions of hydrotherapy and mud pack therapy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intermittent balneological treatment for 5 weeks (10 sessions of hydrotherapy and mud pack therapy)
Number of subjects: 50
Study: 25336596

Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) use
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paper chart use
Number of subjects: 32
Study: 24529387

Group type: EXPERIMENTAL
Intervention: QoL assessment at baseline (P1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recalibration then‐test (P3)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Coping mechanisms by age group
Number of subjects: 66
Study: 22303437

Group type: COMPARATOR
Intervention: CQ
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: CQ+AS
Number of subjects: 308

Group type: COMPARATOR
Intervention: SP
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: SP+AS
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: CQ+PQ
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: SP+PQ
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: AS
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: PQ
Number of subjects: 308
Study: 19542238

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (Nebido)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17498576

Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Bare-Metal Stent (BMS)
Number of subjects: 320
Study: 15825711

Group type: EXPERIMENTAL
Intervention: FGF 1 l.min(‐1)
Number of subjects: 77

Group type: COMPARATOR
Intervention: FGF 2 l.min(‐1)
Number of subjects: 77
Study: 11577783

Group type: EXPERIMENTAL
Intervention: Hemabate (PGF2alpha)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Syntometrine (ergometrine and syntocinon)
Number of subjects: 529
Study: 9613912

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide, 2 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone, 0.6 mg/kg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone, 0.6 mg/kg and nebulized budesonide, 2 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Oral placebo and nebulized placebo
Number of subjects: 198
Study: 1312763

Group type: EXPERIMENTAL
Intervention: Guar (20 grams taken at breakfast)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (polysaccharide-free diet)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Psyllium (20 grams taken at breakfast)
Number of subjects: 8
Study: 3516755

Group type: EXPERIMENTAL
Intervention: 25 mg sodium diclofenac tablet (Novapirina) every 12 hours for 2 consecutive days
Number of subjects: 120

Group type: COMPARATOR
Intervention: 500 mg tablet of acetylsalicylic acid (Aspirin) every 8 hours for 2 consecutive days
Number of subjects: 120
Study: 31334554

Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 100
Study: 29502065

Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LAM) with 6% sevoflurane at 6 L/min for induction and 3% for maintenance
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tracheal intubation with 1.5 mg/kg propofol and 1 µg/kg remifentanil, followed by 0.9 mg/kg rocuronium
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LAM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 52
Study: 26666649

Group type: EXPERIMENTAL
Intervention: TPF (docetaxel plus cisplatin and 5-fluorouracil)
Number of subjects: 75

Group type: COMPARATOR
Intervention: PF (cisplatin and 5-fluorouracil)
Number of subjects: 75
Study: 25561147

Group type: EXPERIMENTAL
Intervention: Sterol milk (Naturcol) for 3 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 35
Study: 22321162

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angle-stable locking compression plate osteosynthesis
Number of subjects: 0
Study: 21147728

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID (D110)
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID (D150)
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study: 17156341

Group type: EXPERIMENTAL
Intervention: CAP-FEIA system (Phadia)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RAST (radioallergosorbent test)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RAST in patients with anaphylactic shock and negative skin tests
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CAP-FEIA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RAST
Number of subjects: 45
Study: 15659242

Group type: EXPERIMENTAL
Intervention: Rivastigmine high-dose therapy
Number of subjects: 37
Study: 12516679

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (MTB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Excel (PTB1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sonicare Elite (PTB2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased toothbrush force from 90 g to 150 g
Number of subjects: 0
Study: 9805520

Group type: EXPERIMENTAL
Intervention: Human interactive personal contact with a member of an ICBC‐trained head restraint adjustment team
Number of subjects: 1974

Group type: COMPARATOR
Intervention: Passive video presentation of the consequences of correct and incorrect head restraint adjustment
Number of subjects: 1974

Group type: COMPARATOR
Intervention: Interactive three‐dimensional kinetic model showing the consequences of correct and incorrect head restraint adjustment
Number of subjects: 1974

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1974
Study: 8543519

Group type: EXPERIMENTAL
Intervention: Pemoline 18.75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemoline 37.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemoline 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemoline 112.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2102705

Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 400 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 600 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 200 mg/d (three times a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 200 mg/d
Number of subjects: 24
Study: 7406481

Group type: EXPERIMENTAL
Intervention: Alafosfalin 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alafosfalin 2500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alafosfalin 500 mg plus Cephalexin 250 mg
Number of subjects: 0
Study: 30247174

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) with daclatasvir for 24 weeks without ribavirin (RBV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) with ledipasvir for 24 weeks without ribavirin (RBV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Treated patients (SOF/daclatasvir or SOF/ledipasvir)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 150
Study: 25587090

Group type: EXPERIMENTAL
Intervention: Computer-guided quality improvement intervention
Number of subjects: 38725
Study: 23900590

Group type: EXPERIMENTAL
Intervention: Accu‐Chek Aviva Expert meter with an integrated bolus advisor
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard BG meter and manual bolus calculation (Control group)
Number of subjects: 218
Study: 21788433

Group type: EXPERIMENTAL
Intervention: Unshorn sheep (treatment group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Shorn sheep (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Post-shearing (treatment group)
Number of subjects: 14
Study: 19800566

Group type: EXPERIMENTAL
Intervention: Constant-frequency TENS (80 pps)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Frequency-modulated TENS (20 to 100 pps)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo TENS (no current)
Number of subjects: 36
Study: 17074563

Group type: EXPERIMENTAL
Intervention: Low-intensity laser treatment
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1052
Study: 14992903

Group type: EXPERIMENTAL
Intervention: Pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg/h infusion for 24 hours)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study: 11720319

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1,000 mg/d for 2 weeks (n = 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metronidazole 20 mg/kg/d for 2 weeks (n = 9)
Number of subjects: 16
Study: 9385282

Group type: EXPERIMENTAL
Intervention: Nasal calcitonin 200 IU per day, divided in 2 doses
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 8015793

Group type: EXPERIMENTAL
Intervention: Upper joint space lavage
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no lavage)
Number of subjects: 33
Study: 2689468

Group type: EXPERIMENTAL
Intervention: Knowledge about asthma
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Behavioral adjustment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Educational interventions
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Health locus of control
Number of subjects: 91
Study: 4895341

Group type: EXPERIMENTAL
Intervention: Sodium salicylate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 13
Study: 31404548

Group type: EXPERIMENTAL
Intervention: High CO state
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Low CO state without ECMO
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Transition from high CO
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Transition to low CO
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Transition risk to ECMO
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Low CO and ECMO
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: High SVR state
Number of subjects: 214
Study: 31163974

Group type: EXPERIMENTAL
Intervention: Intensive volume removal with stepped pharmacological therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fixed rate ultrafiltration
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Increase in renal tubular injury biomarkers
Number of subjects: 105
Study: 28199818

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once per day)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sunitinib (50 mg once per day; 4 weeks on, 2 weeks off)
Number of subjects: 157
Study: 25956286

Group type: EXPERIMENTAL
Intervention: Lidose-isotretinoin (Cip-Iso)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Accutane®
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 358
Study: 23464664

Group type: EXPERIMENTAL
Intervention: Teneligliptin 10 mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Teneligliptin 40 mg
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 21318604

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 60
Study: 18590587

Group type: EXPERIMENTAL
Intervention: NOPE-EGCG treatment (85 mg NOPE and 50 mg EGCG per capsule, two capsules per day)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 138
Study: 16466471

Group type: EXPERIMENTAL
Intervention: Internet mode of health and health behavior questionnaires
Number of subjects: 270

Group type: COMPARATOR
Intervention: Paper mode of health and health behavior questionnaires
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Internet mode
Number of subjects: 270